Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Pyruvic Acid × Clear all
NCT05472220 2022-12-27

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

University of California, San Francisco

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT02911467 2020-07-24

MR

University of California, San Francisco

Phase 1 Terminated
8 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡